The Impact Of Extended Adjuvant Endocrine Therapy For Hormone Receptor Positive Early Breast Cancer:a Meta-Analysis

Objective: Based on the results of clinical trials at home and abroad,to evaluate the effect of extended endocrine therapy in early breast cancer patients with hormone receptor positive.Data and methods: A systematic literature search was performed using the Chinese journal full-text search data,SAN Antonio,the conference report,the Cochrane diagram book pavilion,ASCO meeting,Pubmed,Embase database,Medline database,the Chinese biomedical literature database,and Wang Fang database and Weipu Chinese periodical database from inception to December 2020.To collect the randomized controlled research literature about the effect of extended endocrine therapy in early breast cancer patients with hormone receptor positive.Literature and relevant data were extracted strictly according to the inclusion and exclusion criteria The primary endpoints were disease-free survival(DFS),overall survival(OS),breast cancer-specific survival(BCSS),and recurrence rate.Meta-analysis was performed using Rev Man software.Funnel plots were used to assess publication biasResults: According to include and exclude standards,11 articles were included in this study involving 29000 patients,Jadad score were higher than 3 points,the results showed that: in terms of disease-free survival,for patients with hormone-receptor-positive early-stage breast cancer,comparing with 5-year standard treatment,the extending of adjuvant endocrine therapy can improve the disease-free survival,(OR=0.87,95%CI:0.75～0.99,P=0.040).However,in terms of overall survival,extending adjuvant endocrine therapy can’t improve overall survival(OR=1.02,95%CI:0.90-1.15;P=0.790),without statistical.In terms of breast-cancer specific survival,extending adjuvant endocrine therapy improve breast-cancer specific survival(OR=0.87,95%CI:0.79-0.96;P=0.004),In terms of recurrence rate,extending adjuvant endocrine therapy reduce the recurrence rate(OR=0.76,95%CI:0.64～0.90,P=0.001).Conclusions: Extended adjuvant endocrine therapy can improve disease-free survival and breast-cancer specific survival,reduce recurrence in patients with hormone-receptor-positive early-stage breast cancer...